Literature DB >> 8127053

Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and delta-aminolevulinic acid.

H Schierbeek1, G J Beukeveld, H van Faassen, F J van Spronsen, K Bijsterveld, E E Venekamp-Hoolsema, B G Wolthers, G P Smit.   

Abstract

Patients with hereditary tyrosinaemia type I (HT) excrete large amounts of succinylacetone (SA) in urine. Owing to structural resemblance of SA to delta-aminolevulinic acid (ALA), SA inhibits the second enzyme in the pathway for haeme biosynthesis, porphobilinogen synthase, resulting in increased urinary ALA excretion. We investigated the relationship between urinary SA and ALA excretions of two patients with different forms of HT (late-infantile and juvenile). In both patients the urinary SA and ALA excretions showed a more or less inverse correlation. The patient with the early-infantile form of HT had a relatively greater increase in urinary SA and ALA excretions in comparison to the patient with the juvenile form of HT. A possible explanation for this unexpected inverse correlation between the urinary excretion of SA and ALA might be a lack of intramitochondrial glycine, a substrate for delta-aminolevulinic acid synthesis. It has been reported previously that high concentrations of SA reversibly and competitively inhibit the transport of glycine through membranes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8127053     DOI: 10.1007/bf00711521

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  23 in total

1.  The occurrence and determination of delta-amino-levulinic acid and porphobilinogen in urine.

Authors:  D MAUZERALL; S GRANICK
Journal:  J Biol Chem       Date:  1956-03       Impact factor: 5.157

2.  Nucleotide sequence of cDNA encoding human fumarylacetoacetase.

Authors:  E Agsteribbe; H van Faassen; M V Hartog; T Reversma; J W Taanman; H Pannekoek; R F Evers; G M Welling; R Berger
Journal:  Nucleic Acids Res       Date:  1990-04-11       Impact factor: 16.971

3.  Regulation of 5-aminolevulinate synthase in mouse erythroleukemic cells is different from that in liver.

Authors:  C J Elferink; S Sassa; B K May
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

4.  Hereditary tyrosinemia and abnormal pyrrole metabolism.

Authors:  E S Kang; P S Gerald
Journal:  J Pediatr       Date:  1970-09       Impact factor: 4.406

5.  Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia.

Authors:  R Berger; G P Smit; S A Stoker-de Vries; M Duran; D Ketting; S K Wadman
Journal:  Clin Chim Acta       Date:  1981-07-18       Impact factor: 3.786

6.  Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.

Authors:  S Lindstedt; E Holme; E A Lock; O Hjalmarson; B Strandvik
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

7.  The effects of succinylacetone (4,6-dioxoheptanoic acid) on delta-aminolevulinate synthase activity and the content of heme in monolayers of chick embryo liver cells.

Authors:  N Schoenfeld; Y Greenblat; O Epstein; A Atsmon
Journal:  Biochim Biophys Acta       Date:  1982-12-30

8.  Accumulation of porphobilinogen deaminase, uroporphyrinogen decarboxylase, and alpha- and beta-globin mRNAs during differentiation of mouse erythroleukemic cells. Effects of succinylacetone.

Authors:  B Grandchamp; C Beaumont; H de Verneuil; Y Nordmann
Journal:  J Biol Chem       Date:  1985-08-15       Impact factor: 5.157

9.  Inhibition of heme synthesis in bone marrow cells by succinylacetone: effect on globin synthesis.

Authors:  N Beru; K Sahr; E Goldwasser
Journal:  J Cell Biochem       Date:  1983       Impact factor: 4.429

10.  Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia.

Authors:  E Christensen; B B Jacobsen; N Gregersen; H Hjeds; J B Pedersen; N J Brandt; U B Baekmark
Journal:  Clin Chim Acta       Date:  1981-11-11       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.